Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dimethyl fumarate controlled release - Forward Pharma

Next Previous
Search
Drug Profile

Dimethyl fumarate controlled release - Forward Pharma

Alternative Names: FP-187

Latest Information Update: 14 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Forward Pharma
  • Developer Forward Pharma; Skane University Hospital
  • Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Antirheumatics; Cardiovascular therapies; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF-E2-related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Multiple sclerosis; Plaque psoriasis; Psoriatic arthritis

Most Recent Events

  • 14 Jun 2022 Forward Pharma has patent protection for dimethyl fumarate controlled release in Europe, prior to June 2022
  • 06 Sep 2021 The Technical Board of Appeal of the EPO dismisses Forward Pharma's appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent
  • 04 Jun 2020 Discontinued - Phase-II for Plaque psoriasis in Germany (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top